WO2001035935A3 - Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer - Google Patents

Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer Download PDF

Info

Publication number
WO2001035935A3
WO2001035935A3 PCT/CA2000/001355 CA0001355W WO0135935A3 WO 2001035935 A3 WO2001035935 A3 WO 2001035935A3 CA 0001355 W CA0001355 W CA 0001355W WO 0135935 A3 WO0135935 A3 WO 0135935A3
Authority
WO
WIPO (PCT)
Prior art keywords
endo
exonuclease
cancer
compounds
activity
Prior art date
Application number
PCT/CA2000/001355
Other languages
French (fr)
Other versions
WO2001035935B1 (en
WO2001035935A2 (en
Inventor
Terry Chow
Chiaoli Yeh
David Griller
Leonard Yuen
Original Assignee
Oncozyme Pharma Inc
Terry Chow
Chiaoli Yeh
David Griller
Leonard Yuen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK00975725T priority Critical patent/DK1231910T3/en
Application filed by Oncozyme Pharma Inc, Terry Chow, Chiaoli Yeh, David Griller, Leonard Yuen filed Critical Oncozyme Pharma Inc
Priority to AT00975725T priority patent/ATE431734T1/en
Priority to US10/129,546 priority patent/US7115665B1/en
Priority to CA002388674A priority patent/CA2388674C/en
Priority to AU13765/01A priority patent/AU780538B2/en
Priority to JP2001537928A priority patent/JP2003515534A/en
Priority to DE60042245T priority patent/DE60042245D1/en
Priority to EP00975725A priority patent/EP1231910B1/en
Publication of WO2001035935A2 publication Critical patent/WO2001035935A2/en
Publication of WO2001035935A3 publication Critical patent/WO2001035935A3/en
Publication of WO2001035935B1 publication Critical patent/WO2001035935B1/en
Priority to US11/420,358 priority patent/US20060276548A1/en
Priority to US12/199,603 priority patent/US20090068094A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine. The invention also includes a method for diagnosing cancer and monitoring its progression. This aspect of the invention involves isolating serum from a patient; measuring the concentration of endo-exonuclease in said serum and determining whether said concentration is above a predetermined mean.
PCT/CA2000/001355 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer WO2001035935A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2001537928A JP2003515534A (en) 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity for cancer treatment
AT00975725T ATE431734T1 (en) 1999-11-16 2000-11-16 PENTAMIDINE FOR THE TREATMENT OF CANCER
US10/129,546 US7115665B1 (en) 2000-11-16 2000-11-16 Inhibitors of endo-exonuclease activity for treating cancer
CA002388674A CA2388674C (en) 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity for treating cancer
AU13765/01A AU780538B2 (en) 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity for treating cancer
DK00975725T DK1231910T3 (en) 1999-11-16 2000-11-16 Pentamidine for the treatment of cancer
DE60042245T DE60042245D1 (en) 1999-11-16 2000-11-16 PENTAMIDINE FOR THE TREATMENT OF CANCER
EP00975725A EP1231910B1 (en) 1999-11-16 2000-11-16 Pentamidine for treating cancer
US11/420,358 US20060276548A1 (en) 1999-11-16 2006-05-25 Inhibitors of endo-exonuclease activity for treating cancer
US12/199,603 US20090068094A1 (en) 1999-11-16 2008-08-27 Inhibitors of endo-exonuclease activity for treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16568899P 1999-11-16 1999-11-16
US60/165,688 1999-11-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/420,358 Continuation US20060276548A1 (en) 1999-11-16 2006-05-25 Inhibitors of endo-exonuclease activity for treating cancer

Publications (3)

Publication Number Publication Date
WO2001035935A2 WO2001035935A2 (en) 2001-05-25
WO2001035935A3 true WO2001035935A3 (en) 2002-01-03
WO2001035935B1 WO2001035935B1 (en) 2002-02-07

Family

ID=22600019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001355 WO2001035935A2 (en) 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer

Country Status (12)

Country Link
US (2) US20060276548A1 (en)
EP (1) EP1231910B1 (en)
JP (1) JP2003515534A (en)
AT (1) ATE431734T1 (en)
AU (1) AU780538B2 (en)
CA (1) CA2388674C (en)
CY (1) CY1110503T1 (en)
DE (1) DE60042245D1 (en)
DK (1) DK1231910T3 (en)
ES (1) ES2327313T3 (en)
PT (1) PT1231910E (en)
WO (1) WO2001035935A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097794A2 (en) * 2000-06-21 2001-12-27 Georgetown University Inhibitors of matriptase for the treatment of cancer
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
ITMI20021455A1 (en) * 2002-07-02 2004-01-02 Ugo Raffaello Citernesi PHOSPHOLIPIDIC FORMULATIONS OF LEXITROPSINS THEIR PREPARATION AND THERAPEUTIC USE
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
ES2629682T3 (en) 2004-03-29 2017-08-14 University Of South Florida Effective treatment of tumors and cancer with triciribin phosphate
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
KR20070092972A (en) * 2004-12-10 2007-09-14 테무릭크 가부시키가이샤 Remedy for cancer metastasis and cancer metastasis inhibitor
WO2009086485A1 (en) 2007-12-28 2009-07-09 Server Technology, Inc. Power distribution, management, and monitoring systems and methods
CA2758856A1 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
WO2014008592A1 (en) * 2012-07-13 2014-01-16 Oncozyme Pharma Inc. Combinations comprising diamidine compounds and parp inhibitors for use iν treating cancer
CA3086099C (en) 2017-11-16 2023-05-09 Montdorex Inc. Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
CN115998872A (en) * 2020-04-15 2023-04-25 四川大学华西第二医院 Medicine containing endonuclease inhibiting function and anti-tumor application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2145528A1 (en) * 1971-09-11 1973-04-26 Mack Chem Pharm Exonuclease from a sea sponge - useful as a tumour inhibitor and for prod n of 3'-phosphorylated desoxyribotides from dna
US5084480A (en) * 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585957A1 (en) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
DE3872635T2 (en) * 1987-04-09 1992-12-17 Fisons Plc PENTAMIDINE CONTAINING PHARMACEUTICAL COMPOSITIONS.
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US4856528A (en) * 1987-06-26 1989-08-15 John Hopkins University Tumor volume determination
US5204352A (en) * 1987-09-29 1993-04-20 The United States Of America As Represented By The Secretary Of The Army Compounds exhibiting anti-parasitic activity and a method for their use
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
MX16687A (en) * 1988-07-07 1994-01-31 Ciba Geigy Ag BIARILE COMPOUNDS AND PROCEDURE FOR THE PREPARATION.
US5037758A (en) * 1989-01-11 1991-08-06 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Enhanced production of biosurfactant through the use of a mutated B subtilis strain
GB8903438D0 (en) * 1989-02-15 1989-04-05 May & Baker Ltd New compositions of matter
US5352581A (en) * 1989-03-24 1994-10-04 United States/National Institutes Of Health Sensitive yeast genetic system for identifying agents causing double-stranded DNA damage
WO1991009954A1 (en) * 1989-12-27 1991-07-11 Resnick Michael A Novel system for isolating and producing new genes, gene products and dna sequences
US5489524A (en) * 1991-03-26 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein that has a human Rho motif and deoxyribonuclease activity
US5324830A (en) * 1991-03-26 1994-06-28 United States Of America Chimeric protein that has a human RHo Motif and deoxyribonuclease activity
US5283238A (en) * 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US5723288A (en) * 1994-05-06 1998-03-03 The University Of North Carolina At Chapel Hill Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans, and kits useful therefor
US5874283A (en) * 1995-05-30 1999-02-23 John Joseph Harrington Mammalian flap-specific endonuclease
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5916779A (en) * 1995-09-21 1999-06-29 Becton, Dickinson And Company Strand displacement amplification of RNA targets
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
US20020102542A1 (en) * 1997-10-07 2002-08-01 Daikichi Fukushima Polypeptide, cdna encoding the polypeptide, and use of the both
US7115665B1 (en) * 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
EP2298875B1 (en) * 2000-03-08 2015-08-12 Novozymes A/S Variants with altered properties
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2145528A1 (en) * 1971-09-11 1973-04-26 Mack Chem Pharm Exonuclease from a sea sponge - useful as a tumour inhibitor and for prod n of 3'-phosphorylated desoxyribotides from dna
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5084480A (en) * 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DE LUCA ANTONELLA ET AL: "Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells.", INTERNATIONAL JOURNAL OF CANCER, vol. 73, no. 2, 1997, pages 277 - 282, XP001025184, ISSN: 0020-7136 *
PEREZ J M ET AL: "Binding of Pt-pentamidine to nucleosomal DNA. Studies of the antiproliferative activity of the drug against human cancer cells.", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 89, no. 1, 1993, pages 61 - 72, XP010225183, ISSN: 0009-2797 *
TUAN I -Z ET AL: "Pneumocystis carinii pneumonitis following bone marrow transplantation.", BONE MARROW TRANSPLANTATION, vol. 10, no. 3, 1992, pages 267 - 272, XP010225159, ISSN: 0268-3369 *
WAALKES T P ET AL: "PENTAMIDINE CLINICAL PHARMACOLOGIC CORRELATIONS IN MAN AND MICE", CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 11, no. 4, 1970, pages 505 - 512, XP001025185, ISSN: 0009-9236 *

Also Published As

Publication number Publication date
ATE431734T1 (en) 2009-06-15
DE60042245D1 (en) 2009-07-02
ES2327313T3 (en) 2009-10-28
US20060276548A1 (en) 2006-12-07
CY1110503T1 (en) 2015-04-29
WO2001035935B1 (en) 2002-02-07
US20090068094A1 (en) 2009-03-12
AU780538B2 (en) 2005-03-24
EP1231910A2 (en) 2002-08-21
DK1231910T3 (en) 2009-08-31
CA2388674C (en) 2005-01-25
AU1376501A (en) 2001-05-30
EP1231910B1 (en) 2009-05-20
PT1231910E (en) 2009-08-06
CA2388674A1 (en) 2001-05-25
JP2003515534A (en) 2003-05-07
WO2001035935A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
CY1110503T1 (en) PENTAMIDIN FOR CANCER TREATMENT
Xia et al. An anthocyanin-rich extract from black rice enhances atherosclerotic plaque stabilization in apolipoprotein E–deficient mice
WO2007103114A3 (en) Notch inhibition in the treatment or prevention of atherosclerosis
IL245146A0 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
WO2003069332A3 (en) Detection and/or monitoring of synuclein-related diseases
ATE362363T1 (en) USE OF TNF-ALPHA INHIBITORS TO TREAT NERVE ROOT DAMAGE
WO2004009558A3 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2008118148A3 (en) Adiponectin for the treatment and diagnosis of albuminuria
HUP0401501A2 (en) Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
PL1889920T3 (en) In vitro cancer therapy compound identification method
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
BRPI0411364A (en) compounds having phosphatidylinositol 3-kinase inhibitory activity and methods of use thereof
ATE557087T1 (en) Procedure and KIT for the detection of sclerosis proliferative diseases and/or remedies against sclerosis proliferative diseases as well as procedures and KIT to identify proliferative diseases caused by the prevention and/or treatment of sclerosis.
Assanelli et al. Folic acid and vitamin E supplementation effects on homocysteinemia, endothelial function and plasma antioxidant capacity in young myocardial-infarction patients
Akimov et al. Correction of destructive changes in connective tissues of different organs during chronic nitrate and fluoride intoxication by nanosized silica oxide
BR0311136A (en) compound or a pharmaceutically acceptable salt, enanciomer, diastereomer or ester in vivo or mixture thereof, composition, and method for inhibiting the lethal factor (lf) activity released from bacteria in a mammal
Bertolini et al. Novel screening assay for antioxidant protection against peroxyl radical‐induced loss of protein function
WO2000057871A3 (en) Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
ATE547105T1 (en) GLUCOSAMINE AND DERIVATIVES THEREOF AS TRANSGLUTAMINASE INHIBITORS FOR USE IN THE TREATMENT OF NERVOUS SYSTEM DYSFUNCTION
TW200512458A (en) Treatment and diagnostics of cancer
Noh et al. Active principle of kimchi, 3-(4′-hydroxyl-3′, 5′-dimethoxyphenyl) propionic acid, retards fatty streak formation at aortic sinus of apolipoprotein E knockout mice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 2388674

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13765/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10129546

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 537928

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000975725

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000975725

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 13765/01

Country of ref document: AU